What does Esperion Therapeutics, Inc. do?

Jun 22 2025 06:16 PM IST
share
Share Via
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing oral therapies for managing elevated LDL cholesterol. As of March 2025, it reported net sales of $65 million and a net loss of $40 million, with a market cap of $218.21 million.
Overview:
Esperion Therapeutics, Inc. is a lipid management company in the Pharmaceuticals & Biotechnology industry, focused on developing and commercializing oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Financial Snapshot: Net Sales: 65 Million (Quarterly Results - Mar 2025) Net Profit: -40 Million (Quarterly Results - Mar 2025) Market cap: USD 218.21 Million (Micro Cap) Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.12 Return on Equity: 23.06% Price to Book: -0.51 Contact Details: Address: 3891 Ranchero Dr Ste 150, ANN ARBOR MI: 48108-2837 Tel: 1 734 8873903 Fax: 1 302 6555049 Website: http://www.esperion.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News